![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CLCC1 |
Gene summary for CLCC1 |
![]() |
Gene information | Species | Human | Gene symbol | CLCC1 | Gene ID | 23155 |
Gene name | chloride channel CLIC like 1 | |
Gene Alias | MCLC | |
Cytomap | 1p13.3 | |
Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | A0A024R0G0 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
23155 | CLCC1 | HCC1_Meng | Human | Liver | HCC | 3.93e-50 | 8.46e-02 | 0.0246 |
23155 | CLCC1 | HCC2_Meng | Human | Liver | HCC | 1.32e-14 | 1.06e-01 | 0.0107 |
23155 | CLCC1 | HCC1 | Human | Liver | HCC | 7.07e-04 | 2.20e+00 | 0.5336 |
23155 | CLCC1 | HCC2 | Human | Liver | HCC | 3.30e-13 | 3.07e+00 | 0.5341 |
23155 | CLCC1 | Pt13.b | Human | Liver | HCC | 3.96e-04 | 6.67e-02 | 0.0251 |
23155 | CLCC1 | S014 | Human | Liver | HCC | 2.55e-05 | 2.65e-01 | 0.2254 |
23155 | CLCC1 | S015 | Human | Liver | HCC | 9.54e-08 | 3.36e-01 | 0.2375 |
23155 | CLCC1 | S016 | Human | Liver | HCC | 2.97e-04 | 2.80e-01 | 0.2243 |
23155 | CLCC1 | S027 | Human | Liver | HCC | 6.05e-07 | 6.29e-01 | 0.2446 |
23155 | CLCC1 | S028 | Human | Liver | HCC | 4.69e-22 | 7.23e-01 | 0.2503 |
23155 | CLCC1 | S029 | Human | Liver | HCC | 8.87e-19 | 6.86e-01 | 0.2581 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CLCC1 | SNV | Missense_Mutation | c.1271N>C | p.Arg424Thr | p.R424T | Q96S66 | protein_coding | tolerated(0.11) | probably_damaging(0.966) | TCGA-A1-A0SI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
CLCC1 | insertion | Nonsense_Mutation | novel | c.1204_1205insAAGCCAGCGTATGAGCATGACAGAAATTTC | p.Gly402delinsGluAlaSerValTerAlaTerGlnLysPheArg | p.G402delinsEASV*A*QKFR | Q96S66 | protein_coding | TCGA-A7-A0CG-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
CLCC1 | insertion | Frame_Shift_Ins | novel | c.897_898insGGAGAACGGGGTGAACCTGGGAGGCGGAG | p.Leu300GlyfsTer19 | p.L300Gfs*19 | Q96S66 | protein_coding | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD | ||
CLCC1 | SNV | Missense_Mutation | novel | c.187N>A | p.Glu63Lys | p.E63K | Q96S66 | protein_coding | tolerated(0.12) | possibly_damaging(0.9) | TCGA-C5-A2LZ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Unknown | Unknown | PD |
CLCC1 | SNV | Missense_Mutation | novel | c.1576G>C | p.Asp526His | p.D526H | Q96S66 | protein_coding | deleterious(0.02) | benign(0.003) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
CLCC1 | SNV | Missense_Mutation | c.1427N>A | p.Gly476Glu | p.G476E | Q96S66 | protein_coding | tolerated(1) | benign(0.007) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
CLCC1 | SNV | Missense_Mutation | novel | c.1229N>A | p.Gly410Asp | p.G410D | Q96S66 | protein_coding | deleterious(0.04) | probably_damaging(0.91) | TCGA-A6-A565-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unspecific | 5FU | PD |
CLCC1 | SNV | Missense_Mutation | novel | c.947G>T | p.Gly316Val | p.G316V | Q96S66 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3949-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
CLCC1 | SNV | Missense_Mutation | c.1027G>T | p.Ala343Ser | p.A343S | Q96S66 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
CLCC1 | SNV | Missense_Mutation | c.526G>T | p.Asp176Tyr | p.D176Y | Q96S66 | protein_coding | deleterious(0) | possibly_damaging(0.87) | TCGA-AA-A02R-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
23155 | CLCC1 | ION CHANNEL | opioids |
Page: 1 |